NEO

Ketamine One Engages Integral Wealth as Its Market-Maker

Friday, September 24, 2021 - 11:00pm

Established in 2003, Integral Wealth is headquartered in Toronto with offices in Vancouver, Calgary, and Ottawa.

Key Points: 
  • Established in 2003, Integral Wealth is headquartered in Toronto with offices in Vancouver, Calgary, and Ottawa.
  • The Market-Maker has been retained with the objective of maintaining a reasonable market and improving the liquidity of Ketamine Ones shares.
  • Integral will not receive any securities of the Company as compensation, and Integral does not currently own any securities of Ketamine One.
  • Ketamine One and Integral are unrelated and unaffiliated entities; Integral is arms length to the Company.

PowerTap Provides Update on the Development of Its Gen3 Hydrogen Dispensing Units And Provides Clarification of Past Statements

Friday, September 24, 2021 - 9:01pm

As previously reported in the Companys press release of July 8, 2021, the Company's wholly-owned subsidiary, PowerTap Hydrogen Fueling Corp. completed the engineering design of the PowerTap Gen3 Unit.

Key Points: 
  • As previously reported in the Companys press release of July 8, 2021, the Company's wholly-owned subsidiary, PowerTap Hydrogen Fueling Corp. completed the engineering design of the PowerTap Gen3 Unit.
  • The Company has spent an aggregate of US$2.8 million to complete the blueprint design for the PowerTap Gen3 Unit.
  • The Company is currently in discussions with third-party manufacturers to build a prototype based on the completed blueprint design.
  • ABOUT POWERTAP HYDROGEN CAPITAL CORP.
    PowerTap Hydrogen Capital Corp., through its wholly-owned subsidiary, PowerTap Hydrogen Fueling Corp. (PowerTap), is focused on installing hydrogen production and dispensing fueling infrastructure in the United States.

Moonstake Joins Hyper Protect Accelerator, A Startup Incubator Program of IBM

Friday, September 24, 2021 - 3:00am

Over the past 2 years, IBM Hyper Protect Accelerator has enabled 45 of the most exciting and global fintech, healthtech, and insurtech startups.

Key Points: 
  • Over the past 2 years, IBM Hyper Protect Accelerator has enabled 45 of the most exciting and global fintech, healthtech, and insurtech startups.
  • The program is hosted in collaboration with Village Capital who has supported over 1,000 early-stage entrepreneurs through its programs.
  • Finalist companies underwent multiple interviews and were evaluated on both technical and business factors before successfully joining the Cohorts and Friends of Hyper Protect.
  • Founder of Moonstake, Mitsuru Tezuka, comments the following on this momentous occasion: "I am excited to announce that Moonstake is part of the IBM Friends of Hyper Protect Program 2021.

Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London

Thursday, September 23, 2021 - 12:30pm

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.
  • The results which were published in February 2021, indicated that MDMA has the potential to be more effective at treating AUD.
  • This data will assist Awakn's progress by enabling a better design and more efficient execution of its clinical program.
  • Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.

ESG Continues to Thrive With Mackenzie’s New Sustainable ETF, Now Trading on the NEO Exchange

Thursday, September 23, 2021 - 4:31pm

NEO welcomes Mackenzie Investments (Mackenzie) back to the NEO Exchange, with the launch of the Mackenzie Global Sustainable Bond ETF, an actively managed sustainable ETF.

Key Points: 
  • NEO welcomes Mackenzie Investments (Mackenzie) back to the NEO Exchange, with the launch of the Mackenzie Global Sustainable Bond ETF, an actively managed sustainable ETF.
  • The launch of MGSB on the NEO Exchange is an exciting occasion for Mackenzie, remarked Michael Cooke, SVP and Head of Exchange Traded Funds at Mackenzie Investments.
  • We are very pleased to partner once again with Mackenzie Investments as they launch a new ESG solution on the NEO Exchange.
  • The NEO Exchange is a Canadian Tier 1 stock exchange for the innovation economy, bringing together investors and capital raisers within a fair, liquid, efficient, and service-oriented environment.

Logiq Introduces Geofencing, Enabling Marketers to Customize Messaging Based Upon Context of Consumer Location

Thursday, September 23, 2021 - 1:31pm

This solution gives marketers significantly greater precision and personalization in the message they deliver to consumers based upon the context derived from visiting a geofenced region.

Key Points: 
  • This solution gives marketers significantly greater precision and personalization in the message they deliver to consumers based upon the context derived from visiting a geofenced region.
  • LDM also enables marketers to target consumers who have been in a particular location up to 30 days in the past.
  • LDM geofencing uses anonymous data supplied from GPS, RFID, WiFi and cellular protocols, thereby avoiding the use of PII.
  • This allows marketers to deliver a relevant contextual advertising message when a consumer enters a geofenced area without infringing on their privacy.

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Thursday, September 23, 2021 - 12:30pm

These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.

Key Points: 
  • These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.
  • This is the first direct clinical evidence demonstrating the equivalence of psilocybin and LSD on acute psychedelic effects.
  • "While both LSD and psilocybin have a long history in psychiatric research, psilocybin is being studied in a majority of ongoing clinical trials of psychedelics," said Dr. Liechti.
  • MindMed CEO Robert Barrow said, "Investors and researchers alike are eager to understand the similarities between psilocybin and LSD.

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' Impacts

Wednesday, September 22, 2021 - 1:50pm

If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.

Key Points: 
  • If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.
  • In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus.
  • Tryp'sIND application has details on the safety of the drug product, the study protocol, informed consent information for patients, and additional information.
  • The company expects that the psilocybin oral formulation will increase neuroplasticity and therefore, help create healthy neural patterns of hunger and eating.

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some 'War on Drugs' Impacts

Wednesday, September 22, 2021 - 1:50pm

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- The global need for effective mental health treatment has led to the growing push for the legalization of psychedelic therapies, pushing the market into the mainstream. Last week, Michigan Senator Jeff Irwin introduced legislation that would decriminalize the use of mescaline and psilocybin. If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin. In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus. This legislation coupled with the growing body of research that proves the effectiveness of psychedelics against mental health conditions is among the reasons pushing the psychedelic market towards $69 billion by 2026 . As this happens, companies like Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Cybin Inc. (NEO:CYBN), Compass Pathways (NASDAQ:CMPS), PhamaTher (OTCQB:PHRRF) (CSE:PHRM), and Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED) are pushing R&D efforts to develop and test psychedelic therapies for different health conditions. 

Key Points: 
  • If passed, Senate Bill 631 would allow the possession, cultivation, and delivery of mescaline and psilocybin.
  • In addition, the bill will allow practitioners to charge for counseling and spiritual guidance if they use an entheogenic plant or fungus.
  • Tryp'sIND application has details on the safety of the drug product, the study protocol, informed consent information for patients, and additional information.
  • The company expects that the psilocybin oral formulation will increase neuroplasticity and therefore, help create healthy neural patterns of hunger and eating.

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Wednesday, September 22, 2021 - 12:30pm

In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.

Key Points: 
  • In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.
  • This patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.
  • Mydecine believes these properties will be synergistic and particularly important for the effective treatment of patients with severe PTSD and extreme anxiety disorders.
  • Mydecine Innovations Group is headquartered in Denver, Colorado, USA with international offices in Leiden, Netherlands.